Search

everythinglearnresearchcommunity

for

Search:↓

Testosterone with dutasteride improves muscle strength and body composition in trans men.

Inhibiting 5α-reductase increases progesterone levels in late pregnant mares.

Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.

New treatments for Frontal Fibrosing Alopecia show promise, especially finasteride and dutasteride, with most patients seeing improvement or stabilization.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Oral dutasteride improves hair growth, reduces hair loss, and is safe for most patients.

Frontal fibrosing alopecia is a scarring hair loss condition mainly affecting older women, with no known cause and treatments that may help stabilize hair loss.

Dutasteride effectively and safely treats male hair loss for over a year.

The review found that women using hair loss drugs like finasteride and dutasteride rarely reported sexual side effects.

Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.

Alcoholic solvent improves selectivity in key intermediate for finasteride and dutasteride synthesis.

Certain Dibenzo derivatives may help treat prostate cancer.

5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.

5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.

Oral dutasteride works better for hair loss, but has more sexual side effects; intralesional dutasteride is a possible alternative.

5α-Reductase inhibitors do not consistently increase testosterone levels in the blood.

The study suggests hormonal factors may play a role in Frontal Fibrosing Alopecia and that treatments like oral antiandrogens and steroids could be beneficial.

5-alpha reductase inhibitors, like finasteride and dutasteride, may cause depression, but more research is needed to understand why.

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.

Dutasteride and finasteride have similar risk for osteoporosis and fractures in older men.

Two types of 5α-reductase are in dog skin, which might make dutasteride better than finasteride for treating dog hair loss.

Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.

A new liposomal system for applying dutasteride to the skin was developed, showing better skin absorption and stability, potentially improving treatment for hair loss.

Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.

Nanostructured delivery systems could potentially improve hair loss treatment by targeting drugs to hair follicles, reducing side effects and dosage, but the best size, charge, and materials for these systems need further investigation.

The letter is skeptical about the effectiveness of anti-androgen therapy for COVID-19 and calls for strong evidence from clinical trials.

Dutasteride can reduce night-time urination but it doesn't improve sleep quality.

A new method was created to test the effectiveness of Dihydrotestosterone (DHT) inhibitors, like finasteride and dutasteride, in human and fish cells. The results showed fish cells are more sensitive to these treatments, and dutasteride works better than finasteride in all tested cells.

5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.

The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.